WESPAC Advisors LLC Purchases 7,248 Shares of Gilead Sciences, Inc. $GILD

Key Points

• WESPAC Advisors LLC significantly increased its stake in Gilead Sciences, purchasing an additional 7,248 shares, bringing their total holdings to 9,495 shares valued at approximately $1,053,000.
• Insider trading activity included Gilead's CEO Daniel O'day selling 10,000 shares at $111.66 each, while CFO Andrew Dickinson sold 2,500 shares at $113.57 each, indicating a reduction in their ownership stakes.
• Analysts have recently upgraded Gilead Sciences' stock ratings, with target prices ranging from $127.00 to $143.00, suggesting a strong outlook for the company's stock performance.

WESPAC Advisors LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 322.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,495 shares of the biopharmaceutical company's stock after purchasing an additional 7,248 shares during the period. WESPAC Advisors LLC's holdings in Gilead Sciences were worth $1,053,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GILD. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences during the first quarter worth $25,000. Activest Wealth Management grew its stake in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 227 shares during the period. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences during the first quarter worth $29,000. Colonial Trust Advisors grew its stake in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 213 shares during the period. Finally, Core Alternative Capital grew its stake in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 241 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer owned 591,203 shares in the company, valued at approximately $66,013,726.98. This represents a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer owned 159,555 shares in the company, valued at $18,120,661.35. The trade was a 1.54% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,000 shares of company stock worth $9,402,130. Corporate insiders own 0.27% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on GILD shares. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price for the company in a research note on Tuesday, August 19th. Rothschild & Co Redburn boosted their target price on Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research note on Friday, September 12th. Weiss Ratings reissued a "buy (b)" rating on shares of Gilead Sciences in a research note on Saturday, September 27th. Finally, Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $117.17.

Gilead Sciences Stock Up 2.8%

GILD stock opened at $116.78 on Wednesday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The stock has a market capitalization of $144.90 billion, a P/E ratio of 23.26, a P/E/G ratio of 0.77 and a beta of 0.34. The business has a 50-day moving average of $114.41 and a 200-day moving average of $110.06. Gilead Sciences, Inc. has a fifty-two week low of $84.17 and a fifty-two week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences's dividend payout ratio is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.